GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (STU:P09) » Definitions » Cash Ratio

Pacific Biosciences of California (STU:P09) Cash Ratio : 7.85 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Pacific Biosciences of California Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Pacific Biosciences of California's Cash Ratio for the quarter that ended in Sep. 2024 was 7.85.

Pacific Biosciences of California has a Cash Ratio of 7.85. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Pacific Biosciences of California's Cash Ratio or its related term are showing as below:

STU:P09' s Cash Ratio Range Over the Past 10 Years
Min: 0.92   Med: 2.98   Max: 34.39
Current: 7.85

During the past 13 years, Pacific Biosciences of California's highest Cash Ratio was 34.39. The lowest was 0.92. And the median was 2.98.

STU:P09's Cash Ratio is ranked better than
92.26% of 853 companies
in the Medical Devices & Instruments industry
Industry Median: 1.08 vs STU:P09: 7.85

Pacific Biosciences of California Cash Ratio Historical Data

The historical data trend for Pacific Biosciences of California's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California Cash Ratio Chart

Pacific Biosciences of California Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 8.28 14.56 2.93 6.64

Pacific Biosciences of California Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.17 6.64 7.70 6.50 7.85

Competitive Comparison of Pacific Biosciences of California's Cash Ratio

For the Medical Devices subindustry, Pacific Biosciences of California's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Biosciences of California's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Cash Ratio falls into.



Pacific Biosciences of California Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Pacific Biosciences of California's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=579.008/87.142
=6.64

Pacific Biosciences of California's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash Ratio (Q: Sep. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=424.503/54.057
=7.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pacific Biosciences of California  (STU:P09) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Pacific Biosciences of California Cash Ratio Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacific Biosciences of California Business Description

Traded in Other Exchanges
Address
1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Pacific Biosciences of California Headlines

No Headlines